Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort s

Primary tabs

field_vote: 
No votes yet
Publication type: 
Number of included patients: 
References: 
Therapeutic intervention: 
Disease(s): 
Therapeutic Substance(s): 

J Hepatol. 2002
Jul;37(1):78-86.
Improved
prognosis of postoperative hepatocellular carcinoma patients when
treated with functional foods: a prospective cohort study.

Matsui
Y
, Uhara
J
, Satoi
S
, Kaibori
M
, Yamada
H
, Kitade
H
, Imamura
A
, Takai
S
, Kawaguchi
Y
, Kwon
AH
, Kamiyama
Y
.
First Department of Surgery, Kansai Medical
University, 10-15 Fumizono, Moriguchi, Osaka 570-8507, Japan.

Comment in:

BACKGROUND/AIMS: Active hexose correlated
compound (AHCC) is a newly developed functional food. In vitro
experiments have shown that AHCC enhances natural killer cell activity,
and may be considered a potent biological response modifier in the
treatment of cancer patients. However, the effects of AHCC in a clinical
setting have not been reported. We seek to determine whether AHCC can
improve the prognosis of hepatocellular carcinoma (HCC) patients
following surgical treatment. METHODS: A prospective cohort study was
performed from February 1, 1992 to December 31, 2001. A total of 269
consecutive patients with histologically confirmed HCC were studied. All
of the patients underwent resection of a liver tumor. Time to treatment
failure (disease recurrence or death) and ten parameters related to
liver function after surgery were examined. RESULTS: Of the 269
patients, 113 received AHCC orally after undergoing curative surgery
(AHCC group). The AHCC group had a significantly longer no recurrence
period (hazard ratio (HR), 0.639; 95% confidence interval (CI),
0.429-0.952; P=0.0277) and an increased overall survival rate (HR,
0.421; 95% CI, 0.253-0.701; P=0.0009) when compared to the control group
by Cox's multivariate analysis. CONCLUSIONS: This study suggests that
AHCC intake can improve the prognosis of postoperative HCC patients.